Clinical Research Directory

Inclusion Criteria: 1. Patients at or over 18 years old. 2. Have a histologically confirmed diagnosis of prostate adenocarcinoma status post radical prostatectomy who are candidates for salvage postoperative radiotherapy. This includes patients whose Prostate-Specific Antigen (PSA) does not fall to undetectable levels after prostatectomy or that have undetectable PSA after prostatectomy with a subsequent detectable PSA that increases on \> 2 determinations or increases to PSA \> 0.1 ng/ml. It also includes patients with adverse pathologic features at the time of prostatectomy (e.g. positive surgical margin, pathologic T-stage 3-4 disease, pathologic Gleason score 8-10 disease, presence of tertiary Gleason grade 5 disease) or an intermediate- or high-risk Decipher genomic classifier score. 3. No evidence of metastatic disease 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 5. Can complete EPIC-26/IPSS assessments and provide informed consent Exclusion Criteria: 1. Distant metastatic disease 2. Neuroendocrine or small cell histology 3. Prior pelvic radiotherapy which in the opinion of the treating radiation oncologist precludes safe radiation therapy. 4. Has a diagnosis of inflammatory bowel disease, active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe radiation therapy. 5. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.